Skip to main content

In Brief This Week: Genetic Technologies; Exagen Diagnostics; NorDiag, Hain Lifescience

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies released preliminary financial results this week and said that it will report a net profit after tax of A$4.3 million (US$4.3 million) for the half-year ended Dec. 31. The Australian genomic tools firm said that its half-year revenues were more than A$14.2 million, compared to A$5 million for the first half of 2009. In addition, genetic Technologies noted that its cash reserves were around A$8.4 million at the end of the period.

Exagen Diagnostics this week said that it has completed its expansion at the University of New Mexico Science and Technology Park. The firm said over the next year it intends to double its sales force and hire 16 additional employees.

Norwegian firm NorDiag said this week that Hain Lifescience has placed an order for 25 of the firm's Arrow instruments for nucleic acid purification. This is the second year in a row NorDiag has signed an OEM agreement with Hain for the Arrow instruments.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.